SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-22-109418
Filing Date
2022-04-19
Accepted
2022-04-19 16:02:08
Documents
12
Period of Report
2022-03-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K/A d331032d8ka.htm   iXBRL 8-K/A 22277
  Complete submission text file 0001193125-22-109418.txt   148583

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cbay-20220311.xsd EX-101.SCH 2858
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cbay-20220311_lab.xml EX-101.LAB 18703
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cbay-20220311_pre.xml EX-101.PRE 11697
6 EXTRACTED XBRL INSTANCE DOCUMENT d331032d8ka_htm.xml XML 4002
Mailing Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560
Business Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Filer) CIK: 0001042074 (see all company filings)

IRS No.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36500 | Film No.: 22834968
SIC: 2834 Pharmaceutical Preparations